COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING FOR GENOVIS AB (PUBL) DECEMBER 20, 2019

The Extraordinary General Meeting adopted the following resolutions:

The Meeting resolved in accordance with the principal owner’s recommendation to dismiss Mårten Winge, who is leaving the Board at his own request for personal reasons, as well as to elect Sarah Fredriksson to serve as a new director and as Board Chair.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.